COVID-19 Kapanmasının Yaşa Bağlı Makula Dejenerasyonu Tedavisine Etkileri

Yıl 2023, Cilt: 7 Sayı: 2, 247 - 251, 31.08.2023

Serdar Bilici , Kardelen Ezgi Şahin-elarslan

https://doi.org/10.29058/mjwbs.1294394

Öz

Amaç: Yaşa bağlı makula dejenerasyonu (YBMD) olgularında COVID-19 kapanması nedeniyle yaşanan
intravitreal anti-vasküler büyüme faktörü (VEGF) tedavisindeki gecikmenin anatomik ve fonksiyonel
etkilerinin değerlendirilmesi amaçlandı.
Gereç ve Yöntemler: COVID-19 nedeniyle anti-VEGF tedavisine ara verilen YBMD olguları çalışmaya
dahil edildi. Olguların yaş, cinsiyet, tedaviye verilen ara süresi ve tekrar tedavi sonrası enjeksiyon
sayısı ile takip süresi kaydedildi. Karantina öncesi son vizitleri (V0), karantina sonrası ilk (V1) ve son
vizitlerindeki (V2) görme keskinlikleri (GK) ve optik koherans tomografi ile santral makula kalınlığı (SMK)
değerlendirildi. Olgular tedaviye verilen ara süresine göre 18 hafta ve altı (Grup-1) ile 18 hafta üzeri
(Grup-2) olarak alt gruplara ayrıldı.
Bulgular: Çalışmaya yaş ortalaması 73,1 olan 53 olgunun 53 gözü dahil edildi. Pandemi sürecinde
tedaviye verilen ara ortalaması 26,4 ± 10,6 haftaydı. Tekrar tedaviye başlanan olguların ortalama takip
süresi 32,5 (9-52) hafta olup bu süreç içerisinde ortalama 3,84 (1-9) anti-VEGF tedavi uygulanmıştır.
Tüm grupta V0, V1 ve V2 vizitlerindeki ortalama GK sırasıyla 0,78, 0,98 ve 0,89 LogMAR, ortalama
SMK değerleri sırasıyla 371,3, 430,8 ve 334,2 mikron bulunmuştur (Sırasıyla p=0,001 ve p=0,010).
Grup 1’ de V0, V1 ve V2 vizitlerindeki ortalama GK sırasıyla 0,78, 0,89 ve 0,86 LogMAR; ortalama SMK
değerleri sırasıyla 374,5, 378,2 ve 308,2 mikron olarak bulunmuştur (Sırasıyla p=0,272 ve p=0,761).
Grup 2’de V0, V1 ve V2 vizitlerindeki ortalama GK sırasıyla 0,78, 1,03 ve 0,9 LogMAR; ortalama SMK
değerleri sırasıyla 369,6, 457,8 ve 347,5 olarak bulunmuştur (Sırasıyla p=0,006 ve p=0,005).
Sonuç: YBMD olgularında anti-VEGF tedavisine ara verilmesiyle birlikte anatomik ve fonksiyonel olarak
kötüleşme izlenmiştir. Tekrar tedaviye başlanması ile SMK’ da düzelme olmasına rağmen GK kaybı
kalıcı olmuştur.

Anahtar Kelimeler

Anti-vasküler büyüme faktörü, COVID-19, optik koherens tomografi, yaşa bağlı makula dejenerasyonu

Destekleyen Kurum

Yok

Proje Numarası

Yok

Teşekkür

Dr. Esra Gültekin'e istatistiksel analiz yardımı için teşekkür ederiz.

Effects of COVID-19 Lockdown on Age-Related Macular Degeneration Treatment

Öz

Aim: Evaluating the anatomical and functional effects of delay in intravitreal anti-vascular growth factor
(anti-VEGF) treatment due to the COVID-19 lockdown in age-related macular degeneration (AMD)
cases.
Material and Methods: AMD cases in which anti-vascular growth factor (VEGF) treatment was
interrupted due to the COVID-19 lockdown were included in the study. Age, gender, the interval time of
the treatment delay, the number of injections after retreatment, and the follow-up period were recorded.
Visual acuity (VA) and central macular thickness (CMT) of the participants at the last visit before the lockdown (V0), the first (V1), and the last (V2) visit after the lockdown were evaluated. The cases were divided into subgroups based on
delay in treatment: 18 weeks or less (Group-1) and over 18 weeks (Group-2).
Results: 53 eyes of 53 patients with an average age of 73.1 were included in the study. The average delay in the treatment during the
pandemic period was 26.4 ± 10.6 weeks. The average follow-up period after the initiation of retreatment was 32.5 (9-52) weeks, and an
average of 3.84 (1-9) anti-VEGF treatments were carried out during this period. The mean VA of V0, V1, and V2 visits of the whole group
were determined as 0.78, 0.98, and 0.89 LogMAR respectively, and the mean CMT values were found as 371.3, 430.8, and 334.2 microns
respectively (p=0.001, and p=0.010, respectively). The mean VA of V0, V1, and V2 visits were 0.78, 0.89, and 0.86 LogMAR in Group 1 and,
0.78, 1.03, and 0.9 LogMAR in Group 2, respectively (p=0.272, and p=0.006, respectively). The mean CMT values of V0, V1, and V2 visits
were found as 374.5, 378.2, and 308.2 microns in Group 1 and, 369.6, 457.8, and 347.5 in Group 2, respectively (p=0.761, and p= 0.005,
respectively).
Conclusion: In AMD cases, anatomical and functional deterioration was observed with the discontinuation of anti-VEGF therapy. Although
there was an improvement in CMT with re-initiation of treatment, the loss of VA was irreversible.

Anahtar Kelimeler

Age-related macular degeneration, anti-vascular growth factor, COVID-19, optical coherence tomography

Proje Numarası

Yok

Kaynakça

• 1. Friedman DS, O’Colmain BJ, Muñoz B, Tomany SC, McCarty C, de Jong PT, Nemesure B, Mitchell P, Kempen J; Eye Diseases Prevalence Research Group. Prevalence of agerelated macular degeneration in the United States. Arch Ophthalmol 2004;122:564‐572.
• 2. Rosenfeld PJ, Brown DM, Heier JS, Boyer DS, Kaiser PK, Chung CY, Kim RY; MARINA Study Group. Ranibizumab for neovascular age-related macular degeneration. N Engl J Med 2006;355:1419-1431.
• 3. CATT Research Group; Martin DF, Maguire MG, Ying GS, Grunwald JE, Fine SL, Jaffe GJ. Ranibizumab and bevacizumab for neovascular age-related macular degeneration. N Engl J Med. 2011;364:1897-1908.
• 4. Heier JS, Brown DM, Chong V, Korobelnik JF, Kaiser PK, Nguyen QD, Kirchhof B, Ho A, Ogura Y, Yancopoulos GD, Stahl N, Vitti R, Berliner AJ, Soo Y, Anderesi M, Groetzbach G, Sommerauer B, Sandbrink R, Simader C, Schmidt-Erfurth U; VIEW 1 and VIEW 2 Study Groups. Intravitreal aflibercept (VEGF trap-eye) in wet age-related macular degeneration. Ophthalmology 2012;119:2537-2548.
• 5. Nguyen CL, Oh LJ, Wong E, Wei J, Chilov M. Anti-vascular endothelial growth factor for neovascular age-related macular degeneration: a meta-analysis of randomized controlled trials. BMC Ophthalmol 2018;18:130.
• 6. Wecker T, Ehlken C, Bühler A, Lange C, Agostini H, Böhringer D, Stahl A. Five-year visual acuity outcomes and injection patterns in patients with pro-re-nata treatments for AMD, DME, RVO and myopic CNV. Br J Ophthalmol 2017;101(3): 353-359.
• 7. Greenlee TE, Wang VY, Kang H, Ohlhausen ME, Chen AX, Hom GL, Conti TF, Briskin I, Babiuch AS, Singh RP. Consequences of lapses in treatment with vascular endothelial growth factor inhibitors in neovascular age-related macular degeneration in routine clinical practice. Retina 2021;41(3): 581-587.
• 8. Comune C, Laezza MP, Giunta P, D’Andrea L, Cennamo G. Management of anti-VEGF intravitreal treatment at University Hospital Federico II of Naples during COVID-19 pandemic lockdown. Ther Adv Ophthalmol 2020;12:2515841420966861.
• 9. Saleh OA, Jammal H, Alqudah N, Alqudah A, Abu-Yaghi N. Clinical experience in the administration of intravitreal injection therapy at a tertiary university hospital in Jordan during the COVID-19 lockdown. Clin Ophthalmol 2020;14:2473-2480.
• 10. Chatziralli I, Ventura CV, Touhami S, Reynolds R, Nassisi M, Weinberg T, Pakzad-Vaezi K, Anaya D, Mustapha M, Plant A, Yuan M, Loewenstein A; International Retina Collaborative. Transforming ophthalmic education into virtual learning during COVID-19 pandemic: a global perspective. Eye (Lond) 2021;35:1459-1466.
• 11. Borrelli E, Grosso D, Vella G, Sacconi R, Battista M, Querques L, Zucchiatti I, Prascina F, Bandello F, Querques G. Shortterm outcomes of patients with neovascular exudative AMD: the effect of COVID-19 pandemic. Graefes Arch Clin Exp Ophthalmol 2020;258:2621-2628.
• 12. dell’Omo R, Filippelli M, Semeraro F, Avitabile T, Giansanti F, Parmeggiani F, Romano MR, Strianese D, Romano V, Virgili G, Costagliola C. Effects of the first month of lockdown for COVID-19 in Italy: A preliminary analysis on the eyecare system from six centers. Eur J Ophthalmol. 2021;31(5):2252- 2258.
• 13. Yang KB, Feng H, Zhang H. Effects of the COVID-19 pandemic on anti-vascular endothelial growth factor treatment in China. Front Med (Lausanne) 2020;7:576275.
• 14. Finger RP, Daien V, Eldem BM, Talks JS, Korobelnik JF, Mitchell P, Sakamoto T, Wong TY, Pantiri K, Carrasco J. Antivascular endothelial growth factor in neovascular age-related macular degeneration -a systematic review of the impact of anti-VEGF on patient outcomes and healthcare systems. BMC Ophthalmol 2020;20:294.
• 15. Korobelnik JF, Loewenstein A, Eldem B, Joussen AM, Koh A, Lambrou GN, Lanzetta P, Li X, Lövestam-Adrian M, Navarro R, Okada AA, Pearce I, Rodríguez FJ, Wong DT, Wu L. Guidance for anti-VEGF intravitreal injections during the COVID-19 pandemic. Graefes Arch Clin Exp Ophthalmol 2020;258:1149- 1156.
• 16. Teo KYC, Nguyen V, Barthelmes D, Arnold JJ, Gillies MC, Cheung CMG. Extended intervals for wet AMD patients with high retreatment needs: informing the risk during COVID-19, data from real-world evidence. Eye 2021;35:2793-2801.
• 17. Stattin M, Ahmed D, Graf A, Haas AM, Kickinger S, Jacob M, Krepler K, Ansari-Shahrezaei S. The effect of treatment discontinuation during the COVID-19 pandemic on visual acuity in exudative neovascular age-related macular degeneration: 1-year results. Ophthalmol Ther 2021;10(4):935-945.